If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||
  International Journal of Gynecological CancerVolume 17 Issue 2, Pages 325 - 338 Published Online: 17 Oct 2006 Journal compilation © 2008, IGCS and ESGO The official journal of the European Society of Gynecological Oncology
Abstract | References | Full Text: HTML, PDF (Size: 270K) | Related Articles | Citation Tracking  Hormonal therapy in ovarian cancer Copyright 2007, Copyright the Authors Journal compilation KEYWORDS androgen • estrogen • gonadotropin • gonadotropin-releasing hormone • hormonal therapy • ovarian cancer • progesterone Zheng H, Kavanagh JJ, Hu W, Liao Q, Fu S. Hormonal therapy in ovarian cancer. Int J Gynecol Cancer 2007;17:325–338. ABSTRACTOvarian carcinoma continues to be the leading cause of death due to gynecological malignancy. Epidemiologic studies indicate that steroid hormones play roles in ovarian carcinogenesis. Gonadotropins, estrogen, and androgen may be causative factors, while gonadotropin-releasing hormone and progesterone may be protective factors in ovarian cancer pathogenesis. Experimental studies have shown that hormonal receptors are expressed in ovarian cancer cells and mediate the growth-stimulatory or growth-inhibitory effects of the hormones on these cells. Hormonal therapeutic agents have been evaluated in several clinical trials. Most of these trials were conducted in patients with recurrent or refractory ovarian cancer, with modest efficacy and few side effects. Better understanding of the mechanisms through which hormones affect cell growth may improve the efficacy of hormonal therapy. Molecular markers that can reliably predict major clinical outcomes should be investigated further in well-designed trials. Accepted for publication June 7, 2006 | 
|
